List of Excipients in Branded Drug SOLIQUA 100/33

Excipient Strategy and Commercial Opportunities for SOLIQUA 100/33

Last updated: April 26, 2026

What is SOLIQUA 100/33 and what does that imply for excipient strategy?

SOLIQUA 100/33 is a fixed-dose combination of insulin glargine (100 units/mL) and lixisenatide (33 mcg/mL) in a prefilled pen. The product is positioned for once-daily dosing in diabetes management and is formulated as a single injectable aqueous solution intended for subcutaneous administration.

From an excipient and manufacturability standpoint, fixed-dose insulin/GLP-1 receptor agonist combination injectables typically face the same hard constraints:

• Protein stability: insulin glargine must remain chemically and physically stable in the formulation across shelf life and across temperature excursions typical of distribution and use.
• Self-association and viscosity/flow: the formulation must maintain consistent injection behavior through the pen delivery system.
• Chemical compatibility: excipients must avoid degradation pathways that can affect insulin and lixisenatide (oxidation, deamidation routes, adsorption to container surfaces, and pH-dependent stability).
• Device-excipient interactions: adsorption or precipitation that can change dose accuracy or needle flow must be controlled in the pen/cartridge system.

For a commercial excipient strategy, these constraints drive two practical opportunity vectors:

1. Reformulation with “drop-in” compatibility across pen platforms (shelf life and usability).
2. Route-to-market speed by using excipient systems that align with regulatory expectations for injectable peptide/protein combination products.

What excipient “building blocks” matter most for a glargine/lixisenatide solution?

For insulin-and-GLP-1 injectable solutions, the excipient system usually centers on three functions: pH control, antimicrobial protection (if applicable), and solubilization/stabilization. The exact formulation is proprietary, but excipient strategy is largely predictable because the critical parameters are measurable and heavily constrained by peptide/protein behavior.

Core excipient function map (typical for this product class)

Function	Why it matters in SOLIQUA-class products	What to prioritize commercially
pH control / buffering	Drives insulin glargine conformation, affects peptide stability, reduces aggregation risk	Select buffers that preserve stability while supporting device compatibility
Stabilizers / tonicity agents	Maintain peptide solubility and reduce chemical degradation; manage osmolarity for injection comfort	Use widely accepted amino acids or tonicity agents with strong regulatory history
Surfactant / anti-adsorption	Limits surface adsorption to cartridge/needle components and reduces visible particulates or potency loss	Optimize for both container adsorption and injection flow
Chelators (if used)	Reduce metal-catalyzed degradation pathways, especially for peptides	Tune for stability without compromising compatibility
Viscosity and flow modifiers	Ensure consistent delivery through pen mechanics	Target injection consistency over shelf life rather than only at release

Practical excipient decision logic

A commercial excipient program for SOLIQUA’s profile should be structured around:

• Stability first: chemical (potency, deamidation-related pathways), physical (aggregation/particulates), and container adsorption.
• Pen performance: needle flow resistance, bubble formation risk, and dose reproducibility.
• Manufacturing robustness: filtration behavior, hold-time stability, and batch-to-batch variability.

How does the fixed-dose combination change the excipient strategy versus single-agent products?

A SOLIQUA-style combination changes excipient strategy in ways that matter for both R&D cost and competitive positioning.

Interplay effects unique to combinations

Combination issue	Why it changes excipient selection	Commercial impact
Single formulation must stabilize two actives with different degradation sensitivities	pH, ionic strength, and surfactant choice must satisfy both insulin glargine and lixisenatide stability envelopes	Narrows reformulation space and increases development time
Peptide-surface and protein-surface interactions can conflict	Excipient that reduces adsorption for one active can increase precipitation/instability for the other	Raises risk in “copycat” approaches
Device compatibility needs double validation	Pen systems are tuned to specific solution rheology and surface interaction behavior	Requires more bridging studies for reformulations

Development implication

For competitors, the fastest viable “excipient strategy” is usually not a totally new excipient system. It is a controlled optimization aimed at:

• reducing adsorption
• improving physical stability
• maintaining injection flow through a targeted pen device set

What are the commercial opportunities linked to excipient strategy for SOLIQUA 100/33?

Even without changing active ingredients, excipient strategy creates commercial optionality across three lanes: (1) lifecycle extension, (2) supply and platform scaling, and (3) differentiated generics/biosimilars formulation packages.

Opportunity 1: Pen-platform scalability and cost-of-goods reduction

Fixed-dose combination pens require tight control of solution behavior through cartridge materials, needle coatings, and assembly tolerances. Excipient strategy can reduce manufacturing risk and increase throughput by stabilizing:

• filtration performance and recovery
• hold-time potency retention
• adsorption loss to contact surfaces

Commercial levers

• Lower batch failures: excipients that reduce time-dependent degradation reduce rejected lots.
• Shorter release testing windows: improved stability can tighten spec strategies and reduce in-process hold-time burden.
• Supply continuity: robust formulation reduces sensitivity to raw material lot variability (buffer salts, surfactants, amino acids).

Opportunity 2: Differentiated “access” products around dosing experience

Injectable diabetes competitors win by delivering predictable usability and tolerability. Excipient strategy can support:

• consistent injection force
• low risk of visible particulates
• predictable priming and delivery through pen mechanics

This is a commercial path for pipeline products that target:

• better user experience endpoints
• adherence via injection usability

Opportunity 3: Development of next-gen combination pens using validated excipient families

For new combination candidates, excipient families with demonstrated compatibility can reduce platform validation time. The commercial payoff is speed:

• less container-compatibility testing
• reduced stress on pen mechanical validation
• earlier stability milestone completion

For investors and partners, the key is that excipients can be treated like reusable intellectual property in practice: while the excipient selection itself may not be independently protectable in all jurisdictions, the end-to-end stability and device performance package can be.

Opportunity 4: “Formulation-only” leverage in competitive entry

When competing entries are constrained by active ingredient protection, excipient strategy can still be used to:

• improve manufacturability for biosimilar-like pathways
• reduce bridging study burden through better stability comparability
• improve commercial differentiation without changing core actives

What does “excipient strategy” translate into for competitive differentiation?

Competitive differentiation for SOLIQUA 100/33 is usually less about “inventing” excipients and more about controlling performance through the excipient system.

Differentiation parameters to track (actionable for diligence)

Parameter	How it impacts commercial outcome	What to diligence in filings and data rooms
Assay stability over shelf life	Impacts launch readiness and cost of stability testing	Stability tables across temperatures and durations
Physical stability	Impacts patient safety and returns	Particulate/aggregation testing methods and acceptance criteria
Container adsorption	Impacts delivered dose and batch consistency	Loss on adsorption studies for cartridge materials
Injection behavior	Impacts adherence and complaint rates	Rheology and pen performance studies
Filterability and batch yield	Impacts cost-of-goods	Filtration and process hold-time validation

What specific excipient-related diligence questions should drive commercial decisions?

A high-stakes excipient program is not judged on one metric. It is judged on a linked set of stability and usability outcomes.

Due diligence checklist for SOLIQUA-class injectables

• Does the formulation maintain potency without drift under shipping and storage temperature ranges?
• Does it remain physically clear with low particulate counts through accelerated and real-time stability?
• Does it minimize loss to container/needle through surfactant and anti-adsorption design?
• Does it provide consistent delivery force and flow rate through the pen delivery system?
• Does the formulation show manufacturing robustness across raw material lot variability?

How could excipient strategy support lifecycle management and revenue protection?

For the originator, lifecycle management often targets:

• improved pen usability
• stronger stability for extended shelf life (where regulatory and supply chain allow)
• broader distribution that demands stability under less controlled conditions

Excipient strategy supports these by enabling:

• improved temperature excursion tolerance
• reduced risk of precipitation
• improved compatibility with newer cartridge/needle supplier changes

This is also relevant to originator cost structures: stabilizing the formulation can reduce waste and expedite supply scaling.

What regulatory and compliance constraints matter for excipient changes?

Even where excipient changes are considered “minor,” injectable peptide/protein products face strict comparability expectations. Commercially, that means:

• reformulations often trigger comparability packages across chemical, physical, and functional performance
• pen and container changes typically need additional bridging work
• excipient substitution can shift pH microenvironments, ionic strength, and adsorption profiles

The commercial opportunity is therefore highest when excipient strategies are implemented in ways that preserve:

• the formulation’s stability envelope
• pen delivery behavior
• container compatibility

What is the strongest commercial route: new excipient system or optimization?

For SOLIQUA 100/33-class products, the most commercially durable approach is optimization, not reinvention:

• keep the formulation family consistent so stability and device performance remain in-range
• focus changes on small, high-impact parameters (anti-adsorption, pH buffering intensity, tonicity adjustment)
• validate through accelerated, real-time, and pen delivery stress tests

This yields faster timelines and reduces the risk of failing the physical stability and usability endpoints that drive complaints and market access.

Key Takeaways

• SOLIQUA 100/33 is a fixed-dose insulin glargine and lixisenatide aqueous pen product, and the excipient strategy must stabilize both a protein and a peptide while preserving injection performance through the device.
• Excipient value is largely in stability-to-device performance: pH buffering, anti-adsorption behavior, physical clarity, and delivery consistency across shelf life and temperature excursions.
• The most actionable commercial opportunities are platform scalability, cost-of-goods reduction through robustness, and differentiating injection experience without changing core actives.
• For competitive programs, the strongest path is controlled excipient optimization with comparability-driven bridging, not a large formulation reset that increases physical stability and device performance risk.

FAQs

1) Why does excipient strategy matter more in combination pens than in single-agent injectables?

Because one formulation must stabilize two actives with potentially different stability drivers while also maintaining consistent delivery mechanics through the same pen and cartridge materials.

2) Which excipient functions usually create the biggest stability and performance leverage?

Buffering (pH control), anti-adsorption surfactants or equivalent surface-active components, and tonicity/stabilizers that support peptide solubility and reduce physical instability.

3) Can excipient changes improve injection experience without changing the actives?

Yes. Adjustments that stabilize rheology, reduce adsorption-related changes over shelf life, and prevent particulates can improve usability and reduce complaint risk.

4) What are the highest-risk excipient changes for regulatory comparability?

Changes that alter pH microenvironment, ionic strength, surfactant behavior, or container adsorption profiles can trigger expanded comparability packages and device bridging needs.

5) What is the most commercially reliable excipient approach for new entrants?

Optimization using excipient families and performance targets aligned with the originator’s stability and device behavior, supported by rigorous physical stability and pen delivery validation.

References

[1] FDA. SOLIQUA 100/33 (insulin glargine and lixisenatide) prescribing information. U.S. Food and Drug Administration.